HomeApplicationsClinical Testing & Diagnostics Manufacturing Diagnostic Immunohistochemistry Procedures

Diagnostic Immunohistochemistry Procedures

Cell Marque™ IVD antibody staining of colon carcinoma

Diagnostic immunohistochemistry (IHC) is a collection of different techniques devised to identify tissue abnormalities, establish prognoses, and indicate therapeutic options. The basic principle of diagnostic IHC is an antigen-antibody binding reaction where an antibody tagged with an enzyme or a fluorescent dye is used to visualize the localization and distribution of a specific antigen in tissues, or tissue sections. Although histological staining has been the main analytical tool for over a century, several improvements in diagnostic immunohistochemistry (IHC) and molecular analyses have revolutionized the field of modern clinical pathology.

Related Technical Articles

  • Colorectal cancer is a common occurrence among inhabitants of most Western countries, second only to carcinoma of the lung.
  • Immunohistochemistry (IHC) is used to characterize intracellular proteins or various cell surfaces in all tissues. Individual markers or more often panels of various marker proteins can be used to characterize various tumor subtypes, confirm tissue of origin, distinguish metastatic from primary tumor and provide additional information which may be important for prognosis, predicting response to therapy or evaluating residual tumour post-treatment.
  • Water for Clinical Chemistry
  • Immunohistochemistry (IHC) represents an indispensable tool in cancer diagnostics.
  • See All (4)

Related Protocols

Find More Articles and Protocols

Diagnostic IHC and Clinical Pathology

IHC is available as part of the routine service in general pathology laboratories, providing a convenient analytical and diagnostic tool. Although much of clinical diagnostics is still largely based on standard tissue staining, like hematoxylin and eosin (H&E), there are many ways in which IHC assists pathologists in the detection of problematic cases. Diagnostic immunostaining is regularly used to identify early subtle morphological or developmental cellular changes, like proliferation or apoptosis. Clinical antibodies can identify individual cell lineages by binding specific marker proteins. This antibody specificity can also result in false-positive/false-negative results, because immunostaining is sensitive to tissue handling, preservation, and reagent quality. Clinical pathology laboratories minimize testing errors by working under established protocols and training programs while utilizing clinically validated diagnostic antibodies, stains, and reagents. In particular, the development of highly specific monoclonal antibodies to key cell markers has led to the use of diagnostic IHC panels in research and clinical identification of disease states and guidance for surgical pathology.

Diagnostic IHC and Cancers

Most cancers can be identified by a combination of histological staining and diagnostic immunohistochemistry by locating specific antigens in biopsy tissue. Determining an exact tumor type using standard H&E staining of formalin-fixed tissues can be challenging, especially with metastatic and/or poorly differentiated tumors. IHC provides a relatively rapid and simple method to better determine the origin of neoplastic tissue and investigate the behavior or progression of a given neoplasm. Cancer of unknown primary (CUP) is a condition in which cancer metastasis is observed but the primary site is unknown. It is estimated that of all cancers 3-5% cases fall under CUP. For critical CUP and other atypical cases where there is a disagreement in the morphological and clinical data, IHC proves to be important in narrowing the range of diagnostic alternatives. In some cases, it provides significant insights into a tentative diagnosis concerning the cancer phenotype and site of the primary tumor. In IHC, immunostaining proves to be a convenient diagnostic tool to detect many types of cancer, including adenocarcinomas (colon, breast, prostate) and skin.  It is often used in colon cancer (HNPCC/Lynch Syndrome) diagnostics to complement classical detection methods like microsatellite instability (MSI), which is characterized by numerous alterations in a type of repetitive DNA. In skin cancer pathology, it is unreliable to identify intraepidermal melanocytes in standard H&E stained sections, especially on sun-damaged skin. Even close inspection may not help in clearly differentiating pigmented keratinocytes from melanocytes or distinctly delineate the melanocyte density. Thus, many pathologists recommend IHC to differentiate melanoma in situ from its mimics.

Diagnostic IHC and Infectious Agents

Diagnostic immunohistochemistry currently provides a rapid morphologic differential of infections in tissue samples from patients, facilitating rapid diagnostic decisions in patient care. Fluorescein isothiocyanate (FITC)-labeled antibodies have been used to detect pneumococcal antigens in infected tissues. In infectious disease detection, IHC has been very useful in identifying microorganisms that are:

  • difficult to detect by routine or special stains
  • stain poorly
  • present in low numbers
  • non-cultivable

Some diagnostic IHC methods are applied in cases of Hepatitis B, Hepatitis C, Cytomegalovirus infections to confirm infectious agents in tissues using specific antibodies raised against microbial DNA or RNA. Additionally, IHC is used in the detection of several cutaneous infections to identify specific viral and bacterial infections that are difficult to detect with certainty using routine microscopy stains alone. Immunofluorescence assay (IFA) has been extensively used for the detection of pathogens (viral, bacterial, or protozoal) in unfixed tissues in both human and veterinary medicine.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?